Sonoma Pharmaceuticals, Inc. · NASDAQ:SNOA
Sonoma Pharmaceuticals — Investor Presentation (March 2021)
27 slides from Sonoma Pharmaceuticals's investor presentation, Mar 4, 2021
Slide 1: Sonoma Pharmaceuticals, Inc. March 2021
Sonoma Pharmaceuticals, Inc. NASDAQ: SNOA March 2021
Slide 2: Legal Disclaimers
Legal Disclaimers INVESTOR PRESENTATION This communication is for informational purposes only. The information contained herein does not purport to be all - inclusive. T he data contained herein is derived from various internal and external sources. No representation is made as to the reasonableness
Slide 3: Legal Disclaimers: Non-GAAP Financial Measures
Legal Disclaimers NON - GAAP FINANCIAL MEASURES Non - GAAP income (loss) from operations minus non - cash expenses (EBITDAS) is a non - GAAP financial measure. The Company defines operating income (loss) minus non - cash expenses as GAAP reported operating income (loss) minus operating depreciation
Slide 4: About Sonoma
About Sonoma Sonoma Pharmaceuticals is a global healthcare leader for developing and producing stabilized hypochlorous acid ( HOCl ) products for a wide range of applications, including wound care, animal health care, eye care, nasal care, oral care and dermatological conditions. The company’s produ
Slide 5: Investor Highlights
Investor Highlights Diverse global healthcare leader • Focused on billion - dollar Rx and OTC wound care, dermatology, eye, oral and nasal care, disinfectant use and animal health markets • Over 20 years of experience • Robust international partner network • Focused on expanding U.S. partner network
Slide 6: Key Opportunities
Key Opportunities • Expand OTC reach in U.S. in the dermatology, eye, oral and nasal care, disinfectants and wound care markets • Fully commercialize existing products via distribution partners or directly • 21 U.S. FDA clearances as medical devices for Section 510(k) • CEs for over 39 products • Ex
Slide 7: Recent Business Developments
Recent Business Developments • Received new CE marking for Microdacyn 60 ® Eye Care in April 2020 • Entered into expanded distribution agreement with Brill International S.L. Spain for the eye care product and new territories Germany, Italy, Spain, Portugal and UK in May 2020 • Approval by ARTG in A
Slide 8: Sonoma's Microcyn Technology
Sonoma’s Microcyn Technology • Stable triple - action topical technology • A powerful anti - microbial - reduces microbial load, including destruction of biofilms • Anti - inflammatory agent – reduces itch and pain • Anti - pruritic activity • Tissue healing (increased blood/oxygen flow to wound) •
Slide 9: What is Hypochlorous Acid?
What is Hypochlorous Acid? During the activation of neutrophils, respiratory bursts generate hydrogen peroxide (H 2 O 2 ) and the activated granule enzyme myeloperoxidase converts H 2 O 2 to hypochlorous acid (HOCl) • Hypochlorous acid (HOCl) is produced by neutrophils in the body as part of its def
Slide 10: Microcyn Technology microbial load reduction & infection control
Microcyn Technology microbial load reduction & infection control 30 seconds “ in vitro kill time (%) reduction” • MRSA - Staphylococcus aureus 99.999 VRE - Enterococcus faecalis 99.999 • Staphylococcus aureus 99.999 Escherichia coli 99.997 • Acinetobacter baumannii 99.999 Bacteroides fragilis 99.999
Slide 11: Current Research and Development
Current Research and Development • Dermodacyn ® Disinfecting solution study on viability of SARS - CoV - 2, see https://www.sciencedirect.com/science/article/pii/S019567012030339X • Endocyn ® study on cellular toxicity, see https://www.sciencedirect.com/science/article/abs/pii/S0099239917310439 • HO
Slide 12: U.S. Summary
U.S. Summary • FDA - cleared products targeting: • atopic dermatitis, dermal lesions • scar management, • pain and itch relief and other dermatological conditions • eye - lash hygiene • acute and chronic wound care • oral care (dental surgery) • Ability to partner for OTC, Rx, and private labels • R
Slide 13: Attractive U.S. Product Offerings
Attractive U.S. Product Offerings
Slide 14: Robust International Distribution Network
Robust International Distribution Network • Steadily growing existing partner base with broad indications • ISO/FDA registered/CE/EN/MOH/TGA registrations for state - of - the - art Mexico manufacturing facility • Ship to 54 countries globally • 40+ partners in dermatology, eye, wound, oral and nasa
Slide 15: State of the Art Manufacturing Facility
State of the Art Manufacturing Facility • ISO 9001 and 13485 certified • MOH, KFDA, SFDA, KSA, TGA, EN, Biocide and many other national listing/approvals • Shipping to 54 countries • First Rate Logistics • Highest Quality Standards • Flexibility of SKUs and packaging • Highly - trained staff
Slide 16: Europe
Europe
Slide 17: Latin America
Latin America
Slide 18: Asia
Asia
Slide 19: Middle East
Middle East
Slide 20: Animal Health Care
20 NASDAQ: SNOA Animal Health Care • MicrocynAH ® is a family of advanced animal healthcare products that are safe to use on all animals, no matter the species or age • Perfect for hot spots, scratches, skin rashes and ulcers, cuts, burns, post - surgical sites, irritated skin and lacerations. • We
Slide 21: Sonoma Partnership Principles
Sonoma Partnership Principles • Sonoma seeks long - term strategic partnerships, based on win/win business plans; 50/50 mentality with focus on what’s most important to each side. • Regular in - person and phone meetings to strengthen relationships. • “Do what you say and say what you do” mentality
Slide 22: Key Financial Metrics
Key Financial Metrics Quarter Ended Quarter Ended Nine Months Ended Nine Months Ended Dec 31 , 2020* (unaudited) Dec 31, 2019* (unaudited) Dec 31, 2020* (unaudited) Dec 31, 2019* (unaudited) Total Revenues $4,936 $4,395 $16,472 $13,616 Gross Profit $1,995 $2,001 $6,753 $6,469 Operating Expenses $2,1
Slide 23: Balance Sheet Highlights
Balance Sheet Highlights (in thousands) December 31, 2020 (unaudited) March 31, 2020 Assets Cash and cash equivalents 5,541$ 3,691$ Accounts receivable, net 4,408 4,062 Inventories 2,958 2,192 Other current assets 3,305 2,438 Total Current Assets 16,212 12,383 Other assets 2,019 2,178 TOTAL ASSETS 1
Slide 24: Income Statement, Dec. 31, 2020
Income Statement, Dec. 31, 2020 (unaudited, in thousands, except per share amounts) 2020 2019 2020 2019 Revenues 4,936$ 4,395$ 16,472$ 13,616$ Cost of revenue 2,941 2,394 9,719 7,147 Gross profit 1,995 2,001 6,753 6,469 Operating expenses Research and development 33 248 425 856 Selling, general and
Slide 25: Statement of Cash Flows, Dec. 31, 2020
Statement of Cash Flows, Dec. 31, 2020 (unaudited, in thousands) 2020 2019 Net cash (used in) provided by operating activities (1,902)$ (1,000)$ Net cash (used in) provided by investing activities 392 (36) Net cash (used in) provided by financing activities 3,039 1,029 Effect of exchange rates on ca
Slide 26: Revenue Metrics
Revenue Metrics (unaudited, in thousands) 2020 2019 Change % Change Revenue by revenue sources: Human 3,534$ 3,528$ 6$ 0.17% Animal 1,357 853 504 59.09% Other 45 14 31 N/A 4,936$ 4,395$ 541$ 12.31% Revenue by geographic area: United States 1,978$ 2,059$ (81)$ -3.93% Latin America 1,307 1,002 305 30.
Slide 27: Thank You.
Thank You.
Sonoma Pharmaceuticals — Investor Presentation (March 2021) on 6ix